Wall Street's Insights Into Key Metrics Ahead of Abbott (ABT) Q3 Earnings

Core Viewpoint - Analysts forecast Abbott (ABT) to report quarterly earnings of $1.30 per share, reflecting a year-over-year increase of 7.4%, with anticipated revenues of $11.41 billion, marking a 7.3% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been adjusted downward by 0.1% over the past 30 days, indicating a reassessment by covering analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Key Metrics Projections - Analysts estimate 'Net sales- Nutrition' to reach $2.20 billion, a year-over-year change of +6.3% [5]. - 'Net sales- Medical Devices- Diabetes Care' is projected at $2.04 billion, indicating an increase of +18.2% year over year [5]. - 'Net sales- Diagnostics' is expected to be $2.31 billion, reflecting a decrease of -4.4% from the previous year [5]. - 'Net sales- Established Pharmaceuticals' is estimated at $1.53 billion, showing a +9% change year over year [6]. - 'Net sales- Diagnostics- U.S.' is projected at $909.57 million, indicating a decline of -11.9% from the prior year [6]. - 'Geographic Revenue- U.S.' is expected to be $4.38 billion, with a year-over-year change of +4.3% [6]. - 'Geographic Revenue- International' is estimated at $7.02 billion, reflecting a +9.2% change year over year [7]. - 'Net sales- Nutrition- International' is projected to reach $1.23 billion, indicating a +9.8% change [7]. - 'Net sales- Nutrition- U.S.' is expected at $966.71 million, reflecting a +1.8% change [7]. - 'Net sales- Diagnostics- International' is forecasted at $1.40 billion, indicating a +1.3% change [8]. - 'Net sales- Medical Devices- Rhythm Management- U.S.' is projected at $325.63 million, reflecting a +13.1% change year over year [8]. - 'Net sales- Medical Devices- Rhythm Management- International' is expected to reach $339.38 million, indicating a +9.8% change year over year [9]. Stock Performance - Abbott shares have returned +0.5% over the past month, compared to the Zacks S&P 500 composite's +3.5% change, with a Zacks Rank 3 (Hold), suggesting that ABT is expected to mirror the overall market performance in the near future [9].